<DOC>
	<DOC>NCT00150215</DOC>
	<brief_summary>The purposes of this study are: - To determine the safety, tolerability and pharmacokinetics of single doses of PF-00184562; and - To explore the exposure-response relationship of neuropsychometric and tolerability measures of PF-00184562 compared to olanzapine.</brief_summary>
	<brief_title>A First In Human Study Of PF-00184562 In Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Healthy male or female subjects of nonchildbearing potential Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, pancreatic, psychiatric, neurologic, active infections, immunological, or allergic disease (including drug allergies and seasonal allergies at time of dosing).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2006</verification_date>
</DOC>